A 2-in-1 adaptive Phase 2/3 design was proposed by Chen et al. The 2-in-1 design improves the overall clinical trial development efficiency by 1) building in an early and informative decision-making; 2) allowing the flexible endpoint-usage at the decision and the final analysis; 3) potential registration path forward in either Phase 2 or Phase 3. The original paper illustrates a general idea. In this paper, we extend this design to fit more common scenarios. The type I error control in the extended 2-in-1 adaptive Phase 2/3 designs is investigated in both simulation and theoretical ways.
Keywords: 2-in-1 adaptive design; Dual primary endpoints; Group sequential design; Multiple interim analyses; Type I error.
Copyright © 2020 Elsevier Inc. All rights reserved.